[{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"VYNE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"VYNE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"VYNE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Journey Medical Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Divestment","leadProduct":"Minocycline Hydrochloride","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"VYNE Therapeutics","amount2":0.47999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0.47999999999999998,"dosageForm":"Topical Foam","sponsorNew":"VYNE Therapeutics \/ Journey Medical Corporation","highestDevelopmentStatusID":"12","companyTruncated":"VYNE Therapeutics \/ Journey Medical Corporation"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"VYN201","moa":"BET","graph1":"Immunology","graph2":"Preclinical","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"VYNE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"VYNE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"VYNE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"VYNE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"VYN201","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"VYN201","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"VYN201","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"VYN201","moa":"","graph1":"Dermatology","graph2":"Phase I","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"VYNE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"VYN201","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"VYNE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"VYN202","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"VYNE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Access Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"VYN201","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.089999999999999997,"dosageForm":"Ointment","sponsorNew":"VYNE Therapeutics \/ Access Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Access Biotechnology"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"LifeSci Capital LLC","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"VYN201","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"VYNE Therapeutics \/ LifeSci Capital LLC","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ LifeSci Capital LLC"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"VYN202","moa":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"VYNE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"VYN201","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"VYN201","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"VYN202","moa":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"VYNE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"VYN202","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"VYNE Therapeutics \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by VYNE Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target